Highlights from ASCO GU 2017 - Results from #60

Viewing 61-80 of 100 articles

ASCO GU 2017: Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial. - Poster Session Highlights

ASCO GU 2017: Can focal therapy impact perioperative, oncological, and functional outcomes in men who underwent focal therapy salvage robotic-assisted radical prostatectomy? A retrospective matched-pair comparative study. - Poster Session Highlights

ASCO GU 2017: Twitter mentions and academic citations in the urologic oncology literature. - Poster Session Highlights

ASCO GU 2017: The diverse genomic landscape of low-risk prostate cancer. - Poster Session Highlights

ASCO GU 2017: The importance of surgical margins for biochemical recurrence in high-risk prostate cancer patients. - Poster Session Highlights

ASCO GU 2017: Best of Journals Prostate Cancer: Medical Oncology View - Session Highlights

ASCO GU 2017: The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients. - Poster Session Highlights

ASCO GU 2017: Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy. 2 - Poster Session Highlights

ASCO GU 2017: Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer - Poster Session Highlights

ASCO GU 2017: Best of Journals: Prostate Cancer: Radiation Oncology View - Session Highlights

ASCO GU 2017: Best of Journals Prostate Cancer: Urology View - Session Highlights

ASCO GU 2017: Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review - Poster Session Highlights

ASCO GU 2017: Effects of Radium-223 with Docetaxel vs. Docetaxel alone on Bone Biomarkers in Patients with Bone-Metastatic Castration Resistant Prostate Cancer mCRPC: A Phase I/IIa Clinical Trial - Poster Session Highlights

ASCO GU 2017: Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy. - Poster Session Highlights

ASCO GU 2017: Targeting reciprocal feed back inhibition: Apalutamide and everolimus in patients with metastatic castrate resistant prostate cancer - Poster Session Highlights

ASCO GU 2017: Association of changes in circulating cell-free plasma DNA and circulating tumor cells during treatment with clinical outcome from Olaparib in CRPC: exploratory analyses from the TOPARP-A trial

ASCO GU 2017: The utility of Imaging In challenging Cases with High Risk, Recurrent, and Advanced Prostate Cancer - Radiologist - Session Highlights

ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Radiation Oncologist - Session Highlights

ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Medical Oncologist - Session Highlights

ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Surgeon - Session Highlights

1
2
3
4
5